Background Pharmacotherapy combinations have been shown to improve survival and reduce hospitalisations in adults with chronic heart failure with reduced ejection fraction (HFrEF); however, their cost ...
Several new treatment combinations have been approved in metastatic renal cell carcinoma (mRCC). To determine the optimal therapy on the basis of cost and health outcomes, we performed a ...
This study examines the availability of cost-effectiveness analyses for medical devices, both in terms of the number of studies and when studies are published. Objectives: Academic researchers and ...
Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice SOC was dominated by ...
Modeling at 2023 net pricing estimated semaglutide would avert >358,000 cardiovascular events/deaths, saving ~$15B in cardiovascular care plus ~$8B in other care, but adding ~$344B lifetime drug spend ...
As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...
Adding sodium-glucose cotransporter 2 (SGLT2) inhibitors to standard medical therapy for heart failure with preserved ejection fraction (HFpEF) provides just low-to-intermediate economic value to the ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Efanesoctocog alfa prophylaxis is conventionally cost-ineffective compared with standard factor VIII ...
Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine. Objective: Migraine is a debilitating chronic disorder requiring multifaceted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results